Mounjaro (Tirzepatide) Injection Pen – 15 mg

Introduction

The Mounjaro (Tirzepatide) 15 mg Injection Pen is the strongest available strength in the Mounjaro range. It is prescribed once weekly for adults with type 2 diabetes who have advanced through lower doses (2.5 → 5 → 7.5 → 10 → 12.5 mg) and require maximum therapeutic effect. Developed by Eli Lilly, Mounjaro is the first medication to act on both GIP and GLP-1 receptors, offering superior results for blood sugar control and weight loss compared to traditional therapies.

Who Should Use the 15 mg Pen?

The 15 mg pen is suitable for:

• Adults with type 2 diabetes needing advanced glycaemic management.

• Patients who tolerated and benefited from lower doses.

• Individuals seeking stronger, sustained weight reduction alongside diabetes therapy.

⚠️ Not recommended as a starting dose. It is a continuation and escalation dose.

How Mounjaro 15 mg Works

Mounjaro contains tirzepatide, which works through dual incretin action:

• GLP-1 receptor agonist: Increases insulin secretion, slows gastric emptying, lowers glucagon, and reduces appetite.

• GIP receptor agonist: Improves insulin sensitivity and enhances fat metabolism.

Together, these actions provide deep reductions in HbA1c, better post-meal glucose control, and meaningful long-term weight management.

Benefits of Mounjaro 15 mg

1. Maximum Blood Sugar Reduction

   • Lowers fasting and post-meal glucose.

   • Helps maintain HbA1c targets over time.

2. Sustained Weight Loss

   • Enhances satiety and reduces caloric intake.

   • Supports long-term weight management.

3. Cardiometabolic Health

   • May improve cholesterol and triglyceride levels.

   • Can reduce blood pressure and inflammation markers.

4. Convenience

   • Once-weekly injection with a prefilled, easy-to-use pen.

Dosing and Administration

• Stepwise escalation: Begin at 2.5 mg → increase gradually through intermediate doses.

• Ongoing therapy: 15 mg once weekly (maximum recommended dose).

• Administer subcutaneously in abdomen, thigh, or upper arm.

• Rotate injection sites each week.

• 1 pen = 1 dose = 1 week. For a month, patients need 4 pens.

Side Effects

Common:

• Nausea, vomiting, diarrhoea, constipation

• Reduced appetite

Serious (rare):

• Pancreatitis

• Gallbladder problems

• Kidney issues (often due to dehydration)

• Severe allergic reactions

⚠️ Contraindicated in patients with a history of medullary thyroid carcinoma or MEN 2.

Storage

• Keep refrigerated (2°C–8°C).

• Do not freeze.

• Can be stored at room temperature (below 30°C) for up to 21 days.

• Store in original carton, away from light.

Why Choose the 15 mg Pen?

• Strongest therapeutic option in the Mounjaro range.

• Maximum effect on blood sugar control and weight management.

• Convenient once-weekly injection.

• Proven clinical benefits in the SURPASS trials.

Conclusion

The Mounjaro (Tirzepatide) 15 mg Injection Pen is the final step in tirzepatide therapy for type 2 diabetes. It provides maximum glycaemic control, meaningful weight reduction, and long-term metabolic improvements. With once-weekly dosing and proven results, Mounjaro 15 mg helps patients achieve lasting success in managing diabetes and improving overall health.